Sex Differences in the Effects of Inhaled Corticosteroids on Weight Gain among Patients with Asthma
Table 1
Patient demographics.
Characteristics
Women
Men
Percentage of missing information (n)
Sociodemographics
#
109
71
0 (0)
Age, yr#
51.4 ± 13.5
48.3 ± 13.5
2 (4)
White race, % (n)
94 (100)
91 (64)
2 (4)
Education, yr#
12.9 ± 3.4
13.4 ± 3.7
4 (7)
Employed, % (n)
64 (66)
73 (51)
4 (7)
Cohabitating, % (n)
65 (67)
70 (49)
4 (7)
Weight, kg#
67.5 ± 15
87.2 ± 19.3
2 (4)
Baseline BMI, kg/m2
26 ± 5.4
28.1 ± 6.3
2 (4)
Pulmonary function
FEV1, % predicted#
78.0 ± 19.5
76.2 ± 21.5
7 (13)
FVC, % predicted#
88.0 ± 16.3
89.0 ± 20.2
8 (14)
FEV1/FVC, % predicted
72.6 ± 10.7
69.3 ± 10.1
8 (14)
Asthma history
Asthma control (ACQ level)
1.5 ± 1.1
1.4 ± 0.9
2 (4)
Atopic#, % (n)
69 (72)
70 (49)
3 (5)
Asthma medications
Short-acting β 2-agonists#, % (n)
96 (102)
100 (70)
2 (4)
Long-acting β 2-agonists#, % (n)
83 (88)
74 (52)
2 (4)
ICS#, % (n)
100 (106)
99 (69)
2 (4)
ICS dose*#, μg
776 ± 568
716 ± 460
14 (25)
Oral corticosteroids#, % (n)
13 (14)
6 (4)
2 (4)
Antileukotrienes#, % (n)
15 (16)
10 (7)
2 (4)
Antirhinitics#, % (n)
25 (27)
14 (10)
2 (4)
Data are presented as mean ± SD or % (no.). FEV: forced expiratory volume; FVC: forced vital capacity; ICS: inhaled corticosteroids.
*Fluticasone propionate equivalent (μg).
#Used in the multiple imputation process.
